Oncology

pipeline pipes RD research
Biotech

BeOne shelves 5 cancer programs, halts ph. 2 arthritis trial

Four of the five cancer assets have been discontinued entirely, and the company is currently determining next steps for the arthritis candidate.
Darren Incorvaia May 7, 2026 11:15am
Golfer devastated after just barely missing a putt

Amgen abandons cancer, Sjögren’s drugs over weak ph.2 data

May 1, 2026 1:45am
A ballpoint pen rests on top of a stack of documents ready for signing

BeOne signs $2B deal for option on preclinical trispecific

Apr 30, 2026 7:55am
Miels

Why the next blockbuster in GSK CEO's sights could be in cancer

Apr 29, 2026 7:16am
Goal disorientation and lack of vision

Compass Therapeutics' stock heads south after bispecific OS miss

Apr 27, 2026 10:55am
Pfizer booth at AACR 2026

Pfizer cans work on next-gen conjugate in cancer patients

Apr 23, 2026 11:20am
More News

AACR: Revolution rolls on in pancreatic cancer as RAS wave rises

Apr 21, 2026 5:35pm

AACR: Genentech veteran engineers ‘smart’ cancer drug startup

Apr 19, 2026 6:05pm

Terremoto takes $108M series C to fuel trials of AKT1 inhibitors

Apr 15, 2026 7:43am

Revolution’s RAS inhibitor hits key goals in ph. 3 cancer trial

Apr 13, 2026 8:00am